The latest research on Persista Bio’s technology, implanting cells in vivo without immunosuppression, is now available via preprint on bioRxiv. The study shows the reversal of diabetes in rats. Researchers used a macroencapsulation system that enabled effective and practical therapy by providing the cells oxygenation and allowing high density of cells in the capsule. In this study, the implant senses glucose and releases insulin, thereby controlling glucose levels in the body.
The manuscript, “A Continuously Oxygenated Macroencapsulation System Enables High-Density Packing and Delivery of Insulin-Secreting Cells,” has been submitted and is under revision for peer review. It’s available at: https://www.biorxiv.org/content/10.1101/2025.04.21.649806v1 Grateful to our Cornell University and Giner, Inc. co-authors for this work: Tung Pham, Phuong L. Tran, Linda Tempelman, Simon G. Stone, Christopher Piccirillo, Alan Li, James A. Flanders, Minglin Ma. Thanks to sponsors including NIDDK and Breakthrough T1D.